ACTU ▼ -0.7% - Actuate Therapeutics, Inc. Common stock $ACTU - Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib Actuate Therapeutics released preclinical data demonstrating that its drug candidate elraglusib works synergistically when combined with two RAS inhibitors, zoldonrasib and daraxonrasib. Despite the positive preclinical findings, $ACTU declined 0.7% today, suggesting investors may have viewed the results as already priced in or had concerns about the development timeline and path to commercialization. 09-SEP-2026 07:01 AM ET